New hope for EGPA: rituximab shows promise in major trial
NCT ID NCT02807103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether the drug rituximab can help people with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA) achieve remission better than standard treatments. 107 adults with active EGPA were randomly assigned to receive either rituximab or conventional therapy. The main goal was to see if more patients could stop disease activity and lower their steroid dose by day 180.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab (a drug that targets certain immune cells)
What this could lead to
If successful, this could provide a new, targeted treatment option to induce remission in EGPA, potentially reducing reliance on steroids.
What could go wrong
This is a completed Phase 3 trial, but results are not yet widely available. Rituximab may not be more effective than standard therapy and carries risks like infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin
Paris, Paris, 75014, France